CH622261A5 - - Google Patents
Download PDFInfo
- Publication number
- CH622261A5 CH622261A5 CH388676A CH388676A CH622261A5 CH 622261 A5 CH622261 A5 CH 622261A5 CH 388676 A CH388676 A CH 388676A CH 388676 A CH388676 A CH 388676A CH 622261 A5 CH622261 A5 CH 622261A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- compound
- compounds
- methyl
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000001350 alkyl halides Chemical class 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- -1 sulfonyloxy group Chemical group 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 8
- ZWLTVCCOYCMAIM-UHFFFAOYSA-N 9h-pyrido[2,3-b]azepine Chemical compound C1=CC=CN=C2NC=CC=C21 ZWLTVCCOYCMAIM-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- CPGOFLCSFXYBKY-UHFFFAOYSA-N 1,3,13-triazatricyclo[9.4.0.02,7]pentadeca-2(7),3,5,8,10,12,14-heptaene Chemical compound N1=CC=CC=2C=CC=C3N(C=21)C=CN=C3 CPGOFLCSFXYBKY-UHFFFAOYSA-N 0.000 description 2
- PJHKXESPJOFGOA-UHFFFAOYSA-N 1h-azepine;dihydrochloride Chemical compound Cl.Cl.N1C=CC=CC=C1 PJHKXESPJOFGOA-UHFFFAOYSA-N 0.000 description 2
- KVIOIFKWKBDGAV-UHFFFAOYSA-N 58881-41-7 Chemical compound C1=CC=C2N3C(=O)C4=CC5=CC=CC=C5N4C(=O)C3=CC2=C1 KVIOIFKWKBDGAV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000794 anti-serotonin Effects 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- RKUWJHCHNKUFJZ-UHFFFAOYSA-N 1,5,13-triazatricyclo[9.4.0.02,7]pentadeca-2(7),3,5,8,10,12,14-heptaene Chemical compound C1=CN=CC=2N1C1=C(C=CC=2)C=NC=C1 RKUWJHCHNKUFJZ-UHFFFAOYSA-N 0.000 description 1
- XDJWZONZDVNKDU-UHFFFAOYSA-N 1314-24-5 Chemical compound O=POP=O XDJWZONZDVNKDU-UHFFFAOYSA-N 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- AJUMGSLQADLWKL-UHFFFAOYSA-N 1h-azepine;hydrochloride Chemical compound Cl.N1C=CC=CC=C1 AJUMGSLQADLWKL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- DHUHYBBSQWQGSN-UHFFFAOYSA-N 2-(4-methyl-2-phenylpiperazin-1-yl)pyridine-3-carbonitrile Chemical compound C1N(C)CCN(C=2C(=CC=CN=2)C#N)C1C1=CC=CC=C1 DHUHYBBSQWQGSN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JAUPUQRPBNDMDT-UHFFFAOYSA-N 2-chloropyridine-3-carbonitrile Chemical compound ClC1=NC=CC=C1C#N JAUPUQRPBNDMDT-UHFFFAOYSA-N 0.000 description 1
- USIDQCCXMGJOJM-UHFFFAOYSA-N 2-fluoropyridine-3-carbonitrile Chemical compound FC1=NC=CC=C1C#N USIDQCCXMGJOJM-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 238000006824 Eschweiler-Clarke methylation reaction Methods 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FGLAMNFOHWVQOH-UHFFFAOYSA-N N-demethylmirtazapine Chemical compound C1C2=CC=CN=C2N2CCNCC2C2=CC=CC=C21 FGLAMNFOHWVQOH-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- VMPVEPPRYRXYNP-UHFFFAOYSA-I antimony(5+);pentachloride Chemical compound Cl[Sb](Cl)(Cl)(Cl)Cl VMPVEPPRYRXYNP-UHFFFAOYSA-I 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LRESCJAINPKJTO-UHFFFAOYSA-N bis(trifluoromethylsulfonyl)azanide;1-ethyl-3-methylimidazol-3-ium Chemical compound CCN1C=C[N+](C)=C1.FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F LRESCJAINPKJTO-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- KPJPHPFMCOKUMW-UHFFFAOYSA-N iodomethane Chemical compound I[CH2] KPJPHPFMCOKUMW-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N phosphorus trioxide Inorganic materials O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NLAANVRAGE7504075,A NL189199C (nl) | 1975-04-05 | 1975-04-05 | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH622261A5 true CH622261A5 (en, 2012) | 1981-03-31 |
Family
ID=19823518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH388676A CH622261A5 (en, 2012) | 1975-04-05 | 1976-03-29 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4062848A (en, 2012) |
| JP (1) | JPS5942678B2 (en, 2012) |
| BE (1) | BE840362A (en, 2012) |
| CA (1) | CA1076571A (en, 2012) |
| CH (1) | CH622261A5 (en, 2012) |
| DE (1) | DE2614406A1 (en, 2012) |
| DK (1) | DK142498B (en, 2012) |
| ES (2) | ES446634A1 (en, 2012) |
| FI (1) | FI62087C (en, 2012) |
| FR (1) | FR2305986A1 (en, 2012) |
| GB (1) | GB1543171A (en, 2012) |
| HU (1) | HU179401B (en, 2012) |
| IE (1) | IE42969B1 (en, 2012) |
| LU (1) | LU74680A1 (en, 2012) |
| NL (2) | NL189199C (en, 2012) |
| SE (1) | SE422941B (en, 2012) |
| ZA (1) | ZA761756B (en, 2012) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4515792A (en) * | 1982-09-30 | 1985-05-07 | Ciba-Geigy Corporation | Tetracyclic heterocycles and antidepressant compositions thereof |
| JPS6336682A (ja) * | 1986-07-31 | 1988-02-17 | Matsushita Electric Ind Co Ltd | カセツト方式文字放送受信機 |
| JPS63177670A (ja) * | 1987-01-31 | 1988-07-21 | Fujitsu General Ltd | 文字放送受信装置 |
| JPS63215179A (ja) * | 1987-03-03 | 1988-09-07 | Fujitsu General Ltd | 受信装置 |
| PT95522B (pt) * | 1989-10-05 | 1997-08-29 | Sankyo Co | Processo para a preparacao de novos compostos tetraciclicos com accao anti-alergica e anti-asmatica e de composicoes farmaceuticas que os contem |
| EP0539164A1 (en) * | 1991-10-23 | 1993-04-28 | Sankyo Company Limited | Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| EP1067934B1 (en) * | 1998-04-02 | 2003-11-26 | Akzo Nobel N.V. | Oral liquid solution comprising the antidepressant mirtazapine |
| AU781221B2 (en) * | 1999-04-19 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
| YU74201A (sh) | 1999-04-19 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Nova sinteza prstena piperazina |
| US6545149B2 (en) * | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
| CN1680365A (zh) * | 1999-04-19 | 2005-10-12 | 特瓦制药工业有限公司 | 含哌嗪环化合物的新型合成和结晶方法 |
| US6281207B1 (en) * | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| WO2001025185A1 (fr) * | 1999-09-30 | 2001-04-12 | Sumika Fine Chemicals Co., Ltd. | Procede de production de derive de piperazine |
| AU6019900A (en) * | 1999-11-24 | 2001-06-04 | Sumika Fine Chemicals Co., Ltd. | Anhydrous mirtazapine crystals and process for producing the same |
| AU6474200A (en) | 1999-12-13 | 2001-06-18 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a pyridinemethanol compound |
| PL356605A1 (en) * | 2000-01-19 | 2004-06-28 | Akzo Nobel N.V. | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| EP1658850A1 (en) | 2000-02-11 | 2006-05-24 | Akzo Nobel N.V. | The use of mirtazapine for the treatment of sleep disorders |
| IN190478B (en, 2012) * | 2000-11-07 | 2003-08-02 | Sun Pharmaceutical Ind Ltd | |
| US6660730B2 (en) * | 2000-11-27 | 2003-12-09 | Sumika Fine Chemicals Co., Ltd. | Anhydrous mirtazapine and process for preparing the same |
| US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| DE60224078T2 (de) * | 2001-02-12 | 2008-12-04 | N.V. Organon | Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind. |
| US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| EP1370549A4 (en) * | 2001-03-01 | 2005-03-09 | Teva Pharma | METHOD FOR PRODUCING MIRTAZAPINE INTERMEDIATE PRODUCTS |
| US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| CZ296992B6 (cs) * | 2002-10-03 | 2006-08-16 | Zentiva, A.S. | Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| UA83666C2 (ru) * | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
| CA2565996A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| CA2575979A1 (en) * | 2004-08-13 | 2006-02-23 | Omeros Corporation | Novel serotonin receptor ligands and their uses thereof |
| US20060039867A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| JP4848704B2 (ja) * | 2004-08-24 | 2011-12-28 | 住友化学株式会社 | ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法 |
| AU2005275935A1 (en) * | 2004-08-24 | 2006-03-02 | Sumitomo Chemical Company, Limited | Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine |
| TW200631584A (en) * | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| US20090306046A1 (en) * | 2005-06-27 | 2009-12-10 | N.V. Organon | Method of treatment of hormone depletion induced vasomotor symptoms |
| CA2614289A1 (en) * | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| CN1939918B (zh) * | 2005-09-30 | 2010-09-01 | 北京德众万全医药科技有限公司 | 一种米氮平的制备方法 |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
| EP1953150A4 (en) * | 2005-11-14 | 2009-11-04 | Sumitomo Chemical Co | PROCESS FOR PREPARING 2- (4-METHYL-2-PHENYLPIPERAZIN-1-YL) PYRIDINE-3-METHANOL |
| EP1792618A1 (en) | 2005-11-30 | 2007-06-06 | Rainer Freynhagen | R-mirtazapine for the treatment of pain |
| JP2009539760A (ja) * | 2006-03-06 | 2009-11-19 | ナームローゼ・フエンノートチヤツプ・オルガノン | ホルモン枯渇誘発血管運動症状のホルモン療法からの離脱の改良法 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20070270413A1 (en) * | 2006-05-22 | 2007-11-22 | N.V. Organon | Mirtazapine for the treatment of neuropathic pain |
| TW200815370A (en) * | 2006-06-16 | 2008-04-01 | Organon Nv | Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine |
| KR20090064418A (ko) * | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
| JP5192707B2 (ja) * | 2007-03-22 | 2013-05-08 | 住友化学株式会社 | ミルタザピンの製造方法 |
| US20080255348A1 (en) * | 2007-04-11 | 2008-10-16 | N.V. Organon | Method for the preparation of an enantiomer of a tetracyclic benzazepine |
| EP2146993B1 (en) | 2007-04-11 | 2015-08-05 | Merck Sharp & Dohme B.V. | A method for the preparation of mirtazapine |
| JP5635395B2 (ja) * | 2007-04-11 | 2014-12-03 | メルク・シャープ・エンド・ドーム・ベー・フェー | 鏡像異性的に純粋なベンゾアゼピンの調製方法 |
| US7994314B2 (en) * | 2007-04-11 | 2011-08-09 | N.V. Organon | Method for the preparation of an enantiomerically pure benzazepine |
| EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM |
| JP2009018992A (ja) * | 2007-07-10 | 2009-01-29 | Sumitomo Chemical Co Ltd | 光学活性ミルタザピンの製造方法 |
| US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| JP2011526881A (ja) * | 2008-06-25 | 2011-10-20 | ファイザー・インク | ジアリール化合物およびそれらの使用 |
| US20110201804A1 (en) * | 2008-10-22 | 2011-08-18 | Watson Pharma Private Limited | Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN102432594B (zh) * | 2011-11-28 | 2013-09-11 | 山东鲁药制药有限公司 | 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法 |
| CN103509020A (zh) * | 2013-10-21 | 2014-01-15 | 山东鲁药制药有限公司 | 一种米氮平的合成方法 |
| CN104356133A (zh) * | 2014-11-25 | 2015-02-18 | 南京工业大学 | 一种制备抗抑郁药物米氮平的方法 |
| JP6433809B2 (ja) * | 2015-02-20 | 2018-12-05 | 株式会社トクヤマ | １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法 |
| KR102540021B1 (ko) | 2020-12-02 | 2023-06-07 | (주)유케이케미팜 | 대량 생산에 적합한 미르타자핀의 제조방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL129434C (en, 2012) * | 1966-03-12 | |||
| NL7202963A (en, 2012) * | 1972-03-07 | 1973-09-11 | ||
| US3959470A (en) * | 1972-11-28 | 1976-05-25 | Mikhail Davidovich Mashkovsky | Psychotropic medicinal preparation |
-
1975
- 1975-04-05 NL NLAANVRAGE7504075,A patent/NL189199C/xx not_active IP Right Cessation
-
1976
- 1976-03-23 ZA ZA761756A patent/ZA761756B/xx unknown
- 1976-03-23 US US05/669,544 patent/US4062848A/en not_active Expired - Lifetime
- 1976-03-23 IE IE614/76A patent/IE42969B1/en unknown
- 1976-03-26 GB GB12270/76A patent/GB1543171A/en not_active Expired
- 1976-03-29 CH CH388676A patent/CH622261A5/de not_active IP Right Cessation
- 1976-03-30 DK DK142676AA patent/DK142498B/da active Protection Beyond IP Right Term
- 1976-04-01 FI FI760884A patent/FI62087C/fi not_active IP Right Cessation
- 1976-04-02 BE BE165832A patent/BE840362A/xx not_active IP Right Cessation
- 1976-04-02 ES ES446634A patent/ES446634A1/es not_active Expired
- 1976-04-02 JP JP51037678A patent/JPS5942678B2/ja not_active Expired
- 1976-04-02 LU LU74680A patent/LU74680A1/xx unknown
- 1976-04-02 FR FR7609686A patent/FR2305986A1/fr active Granted
- 1976-04-02 SE SE7603931A patent/SE422941B/xx active Protection Beyond IP Right Term
- 1976-04-02 DE DE19762614406 patent/DE2614406A1/de active Granted
- 1976-04-02 CA CA249,439A patent/CA1076571A/en not_active Expired
- 1976-04-05 HU HU76AO437A patent/HU179401B/hu unknown
-
1977
- 1977-05-31 ES ES459348A patent/ES459348A1/es not_active Expired
-
1994
- 1994-04-21 NL NL940007C patent/NL940007I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL7504075A (nl) | 1976-10-07 |
| DK142498B (da) | 1980-11-10 |
| DE2614406C2 (en, 2012) | 1992-02-20 |
| JPS51122099A (en) | 1976-10-25 |
| ES459348A1 (es) | 1978-03-16 |
| CA1076571A (en) | 1980-04-29 |
| NL189199C (nl) | 1993-02-01 |
| FR2305986A1 (fr) | 1976-10-29 |
| DE2614406A1 (de) | 1976-10-14 |
| FI62087C (fi) | 1982-11-10 |
| JPS5942678B2 (ja) | 1984-10-16 |
| BE840362A (fr) | 1976-10-04 |
| US4062848A (en) | 1977-12-13 |
| LU74680A1 (en, 2012) | 1976-11-11 |
| NL940007I2 (nl) | 1994-10-17 |
| ZA761756B (en) | 1977-03-30 |
| FI62087B (fi) | 1982-07-30 |
| SE7603931L (sv) | 1976-10-06 |
| IE42969B1 (en) | 1980-11-19 |
| FI760884A7 (en, 2012) | 1976-10-06 |
| DK142498C (en, 2012) | 1981-07-06 |
| ES446634A1 (es) | 1977-11-01 |
| SE422941B (sv) | 1982-04-05 |
| FR2305986B1 (en, 2012) | 1980-06-13 |
| NL189199B (nl) | 1992-09-01 |
| DK142676A (en, 2012) | 1976-10-06 |
| AU1236176A (en) | 1977-09-29 |
| HU179401B (en) | 1982-10-28 |
| IE42969L (en) | 1976-10-05 |
| NL940007I1 (nl) | 1994-06-01 |
| GB1543171A (en) | 1979-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH622261A5 (en, 2012) | ||
| DE69723846T2 (de) | Verfahren zur Herstellung von Sildenafil | |
| CH637382A5 (de) | Verfahren zur herstellung neuer tetracyclischer pyridin- oder pyrrolderivate. | |
| DE2111071A1 (de) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen | |
| DE2505239C2 (en, 2012) | ||
| DE1670849B2 (de) | Verfahren zur herstellung von 8-acylamino-1,2,3,4-tetrahydroisochinolinen | |
| DE68903680T2 (de) | 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion-2,4-derivate, deren herstellung und verwendung als heilmittel. | |
| DE1695929C3 (de) | 1 ^-Dihydro-1 -hydroxy^-imino^-amino-6-methylpyrimidine sowie ein Verfahren zu deren Herstellung | |
| DE2141616A1 (de) | Verfahren zur Herstellung von Chinazo lindenvaten und neue Chinazolindenvate | |
| DE1967178C2 (de) | Verfahren zur Herstellung von Chinuclidinyl-4-chinolinmethanolderivaten | |
| DE1935671C3 (de) | 2-Aminomethylindole und ihre Salze | |
| CH630902A5 (en) | Process for preparing novel derivatives of 1,2,3,4,4a,10b-hexahydrobenzo(f)isoquinoline. | |
| DE1076691B (de) | Verfahren zur Herstellung von Phenthiazinderivaten | |
| DE2230154A1 (de) | N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung | |
| DE2511599A1 (de) | Pyrroldiazepine und verfahren zu ihrer herstellung | |
| DE3120909C2 (de) | Verfahren zur Herstellung von 7-(N-Äthyl-N-β-hydroxyäthylaminoäthyl)-8-benzyltheophyllin (Bamifyllin) | |
| DE1038047B (de) | Verfahren zur Herstellung von N-aminoalkylierten Iminodibenzylen und deren Salzen | |
| DE1795053A1 (de) | Verfahren zur Herstellung von Verbindungen der Benzodiazepinreihe | |
| DE1817794C3 (de) | Verfahren zur Herstellung von 2-Benzyloxycarbonylglycylamidobenzophenonen | |
| AT330373B (de) | Verfahren zur herstellung von neuen 2- (heteroaryl-methyl) -5,9beta-dialkyl -6,7- benzomorphanen | |
| AT378960B (de) | Verfahren zur herstelllung von neuen imidazo (1,5-a) (1,4)diazepinverbindungen, ihren salzen und optisch aktiven formen | |
| CH561211A5 (en) | Antihypertensive 3-hydrazino pyrido(4,3-c)pyridazines - prepd. by reacting corresp 3-halo cpd. with hydrazines | |
| AT317231B (de) | Verfahren zur Herstellung von neuen Diazepinderivaten sowie deren 5-Oxyden und deren Säureadditionssalzen | |
| AT251765B (de) | Verfahren zur Herstellung von neuen Yohimbanderivaten und von deren Salzen | |
| DE1643458C3 (de) | N-(2-Alkoxybenzoyl)-p-aminobenzoesäure-aminoalkylester sowie deren quartäre Methylammoniumderivate und Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |